Research programme: cyclo-oxygenase-2 inhibitors - Almirall Prodesfarma
Latest Information Update: 22 Aug 2009
At a glance
- Originator Almirall-Prodesfarma
- Developer Almirall S.A
- Class Pyrans; Small molecules
- Mechanism of Action Cyclo-oxygenase 2 inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Rheumatic disorders
Most Recent Events
- 18 Aug 2004 This programme is still in active development
- 19 Sep 2002 Preclinical trials in Rheumatic disorders in Spain (PO)